The MEA doxorubicin market is expected to grow from US$ 42.28 million in 2022 to US$ 52.76 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2022 to 2028.
Both chemotherapy and targeted therapy significantly improve cancer patients' chances of survival and quality of life. These therapies may bring about the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged across the region. Advanced cancer treatments improve patient survival and increase long-term outpatient chemotherapy requirements. More exposure to chemotherapy results in a greater demand for doxorubicin drugs, thereby boosting the market growth across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA doxorubicin market. The MEA doxorubicin market is expected to grow at a good CAGR during the forecast period.
MEA Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
MEA Doxorubicin Market Segmentation
The MEA doxorubicin market is segmented based on drug formulation, application, distribution channel, and country. Based on drug formulation, the MEA doxorubicin market is bifurcated into lyophilized powder and doxorubicin injection. The lyophilized powder segment dominated the market in 2022. Based on application, the MEA doxorubicin market is segmented into breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, and others. The breast cancer segment dominated the market in 2022. Based on distribution channel, the MEA doxorubicin market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2022. Based on country, the MEA doxorubicin market has been categorized into the UAE, Saudi Arabia, South Africa, and rest of MEA. Our regional analysis states that Saudi Arabia dominated the market in 2022.
Accord Healthcare; Baxter International Inc.; Cipla Inc.; Dr. Reddy's Laboratories; Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Meiji Holdings Co., Ltd.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Zydus Cadila are among the leading companies in the MEA doxorubicin market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 42.28 Million |
| Market Size by 2028 | US$ 52.76 Million |
| CAGR (2022 - 2028) | 3.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Drug Formulation
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East & Africa Doxorubicin Market is valued at US$ 42.28 Million in 2022, it is projected to reach US$ 52.76 Million by 2028.
As per our report Middle East & Africa Doxorubicin Market, the market size is valued at US$ 42.28 Million in 2022, projecting it to reach US$ 52.76 Million by 2028. This translates to a CAGR of approximately 3.8% during the forecast period.
The Middle East & Africa Doxorubicin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Doxorubicin Market report:
The Middle East & Africa Doxorubicin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Doxorubicin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Doxorubicin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Doxorubicin Market
